CN114466663B - 以FcRn拮抗剂治疗抗体介导的障碍的方法 - Google Patents

以FcRn拮抗剂治疗抗体介导的障碍的方法

Info

Publication number
CN114466663B
CN114466663B CN202080067562.1A CN202080067562A CN114466663B CN 114466663 B CN114466663 B CN 114466663B CN 202080067562 A CN202080067562 A CN 202080067562A CN 114466663 B CN114466663 B CN 114466663B
Authority
CN
China
Prior art keywords
fcrn
binding
variants
region
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080067562.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN114466663A (zh
Inventor
B·麦肯斯
H·邱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CN114466663A publication Critical patent/CN114466663A/zh
Application granted granted Critical
Publication of CN114466663B publication Critical patent/CN114466663B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080067562.1A 2019-07-25 2020-07-24 以FcRn拮抗剂治疗抗体介导的障碍的方法 Active CN114466663B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878541P 2019-07-25 2019-07-25
US62/878,541 2019-07-25
PCT/US2020/043533 WO2021016571A2 (en) 2019-07-25 2020-07-24 Methods of treating antibody-mediated disorders with fcrn antagonists

Publications (2)

Publication Number Publication Date
CN114466663A CN114466663A (zh) 2022-05-10
CN114466663B true CN114466663B (zh) 2026-01-02

Family

ID=72087159

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080067562.1A Active CN114466663B (zh) 2019-07-25 2020-07-24 以FcRn拮抗剂治疗抗体介导的障碍的方法

Country Status (13)

Country Link
US (1) US20210024620A1 (https=)
EP (1) EP4004039A2 (https=)
JP (2) JP2022542884A (https=)
KR (1) KR20220038432A (https=)
CN (1) CN114466663B (https=)
AU (1) AU2020315925A1 (https=)
BR (1) BR112022001255A2 (https=)
CA (1) CA3148764A1 (https=)
CO (1) CO2022001164A2 (https=)
IL (1) IL290101A (https=)
MX (1) MX2022001038A (https=)
TW (1) TW202120539A (https=)
WO (1) WO2021016571A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240132624A1 (en) 2022-07-27 2024-04-25 Ablynx N.V. Polypeptides binding to a specific epitope of the neonatal fc receptor
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
WO2025008537A1 (en) 2023-07-05 2025-01-09 Ablynx Nv Improved fcrn antagonists for treatment of igg-related diseases and disorders
WO2025041077A1 (en) 2023-08-23 2025-02-27 Sanofi Ctla-4-based lysosomal degraders and uses thereof
TW202535925A (zh) 2023-10-25 2025-09-16 比利時商艾伯霖克斯公司 具有增強的Ｆｃ受體結合之Ｆｃ結構域變體
TW202540169A (zh) 2023-11-08 2025-10-16 法商賽諾菲公司 基於ｃｄ２５的溶酶體降解物及其用途
WO2025144848A1 (en) * 2023-12-27 2025-07-03 Vetmab Biosciences, Inc. FcRn ANTAGONISTS FOR VETERINARY USE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970492A (zh) * 2007-10-31 2011-02-09 Xencor公司 与FcRn结合改变的Fc变体
WO2013046704A2 (en) * 2011-09-30 2013-04-04 Chugai Seiyaku Kabushiki Kaisha THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE
CN106459191A (zh) * 2014-06-12 2017-02-22 豪夫迈·罗氏有限公司 选择具有修饰的FcRn相互作用的抗体的方法
WO2019110823A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
AU2005304624B2 (en) * 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
MX2018012383A (es) * 2011-03-30 2023-03-07 Chugai Pharmaceutical Co Ltd Método para alterar la retención en plasma e inmunogenicidad de la molécula de union al antígeno.
JP6322411B2 (ja) * 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
UA118029C2 (uk) * 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
DK3215528T3 (da) * 2014-11-06 2019-10-07 Hoffmann La Roche Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
CA2978253A1 (en) * 2015-03-09 2016-09-15 Argenx Bvba Methods of reducing serum levels of fc-containing agents using fcrn antagonists
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
EP3625251A1 (en) * 2017-05-15 2020-03-25 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
IL276286B2 (en) * 2018-01-26 2025-07-01 Genzyme Corp FC variants with improved binding to FCRN and extended half-life

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970492A (zh) * 2007-10-31 2011-02-09 Xencor公司 与FcRn结合改变的Fc变体
WO2013046704A2 (en) * 2011-09-30 2013-04-04 Chugai Seiyaku Kabushiki Kaisha THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE
CN106459191A (zh) * 2014-06-12 2017-02-22 豪夫迈·罗氏有限公司 选择具有修饰的FcRn相互作用的抗体的方法
WO2019110823A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis

Also Published As

Publication number Publication date
CN114466663A (zh) 2022-05-10
CA3148764A1 (en) 2021-01-28
AU2020315925A1 (en) 2022-03-03
EP4004039A2 (en) 2022-06-01
MX2022001038A (es) 2022-04-26
IL290101A (en) 2022-03-01
TW202120539A (zh) 2021-06-01
JP2025098167A (ja) 2025-07-01
WO2021016571A2 (en) 2021-01-28
JP2022542884A (ja) 2022-10-07
WO2021016571A3 (en) 2021-03-04
KR20220038432A (ko) 2022-03-28
BR112022001255A2 (pt) 2022-06-14
CO2022001164A2 (es) 2022-03-08
US20210024620A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
CN114466663B (zh) 以FcRn拮抗剂治疗抗体介导的障碍的方法
CN111788221B (zh) 具有与FcRn增强的结合及延长的半衰期的Fc变体
US20250376526A1 (en) Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY
EP4041398A1 (en) Hybrid antibody
KR20260047593A (ko) 최적화된 Fc 분자
RU2795592C2 (ru) Варианты fc с повышенным связыванием с fcrn и пролонгированным периодом полувыведения
BR122024014725A2 (pt) Usos de um antagonista de fcrn no tratamento de distúrbios mediados por anticorpos com antagonistas de fcrn, polipeptídeos isolados, e composições farmacêuticas compreendendo os mesmos
WO2025125137A1 (en) Baff specific antibodies
CN118103404A (zh) 抗vegfr1抗体及其用途
CN117794949A (zh) 抗体优化

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant